<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550275</url>
  </required_header>
  <id_info>
    <org_study_id>AOI 201409</org_study_id>
    <nct_id>NCT02550275</nct_id>
  </id_info>
  <brief_title>Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging</brief_title>
  <acronym>COSIMH</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <brief_summary>
    <textblock>
      Huntington's disease is a rare genetic neurodegenerative disease. It is accompanied by&#xD;
      movement disorders, cognitive and behavioral. The social behavior of patients are changed,&#xD;
      affecting interpersonal relationships. Patients with Huntington's disease are described as&#xD;
      self-centered, lacking sympathy and empathy and mentally inflexible. These behavioral&#xD;
      problems can be a major source of anxiety for patients and their families. These disorders&#xD;
      also have a negative impact cognitive and motor symptoms as well as the functional abilities&#xD;
      and the quality of life of patients and their entourage. Authors have suggested that these&#xD;
      problems could be related inter alia to social cognition disorders. This concept refers to a&#xD;
      set of skills and emotional and social experiences that regulate relations between&#xD;
      individuals and can explain the behavior of individuals and groups. The objective is to&#xD;
      evaluate disorders of social cognition, which may account for behavioral changes in&#xD;
      Huntington's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the achievement of social cognition process in Huntington's disease using the total score of the scale 15-TOM</measure>
    <time_frame>3 months after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>presymptomatic patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient with Unified Huntington's Disease Rating Scale (UHDRS) &lt; 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>symptomatic patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient with Unified Huntington's Disease Rating Scale (UHDRS) &gt; 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>unaffected patient with Huntington's disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>neuropsychological test</intervention_name>
    <arm_group_label>controls</arm_group_label>
    <arm_group_label>presymptomatic patient</arm_group_label>
    <arm_group_label>symptomatic patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>controls</arm_group_label>
    <arm_group_label>presymptomatic patient</arm_group_label>
    <arm_group_label>symptomatic patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all particpipants&#xD;
&#xD;
          -  Patient gave its written consent&#xD;
&#xD;
          -  between 20 and 70 years&#xD;
&#xD;
          -  School level : at least 7 years&#xD;
&#xD;
          -  native language: french&#xD;
&#xD;
        For presymptomatic patient&#xD;
&#xD;
          -  Huntington's disease diagnosed with abnormal number of CAG repeats: 36 &lt; nucleotide&#xD;
             expansion (CAG)&#xD;
&#xD;
          -  Unified Huntington Disease Rating Scale moteur â‰¤ 5&#xD;
&#xD;
        For symptomatic patient&#xD;
&#xD;
          -  Huntington's disease diagnosed with abnormal number of CAG repeats: 36 &lt; nucleotide&#xD;
             expansion (CAG)&#xD;
&#xD;
          -  Unified Huntington Disease Rating Scale moteur &gt; 5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No national health insurance affiliation&#xD;
&#xD;
          -  Being under guardianship&#xD;
&#xD;
          -  Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart&#xD;
             valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body,&#xD;
             Renal failure, hypersensitivity of Gadolinium) or refusing MRI&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patient with involuntary movement hampering the realization of MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SCHERER GAGOU</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

